189 related articles for article (PubMed ID: 38228036)
1. NDRG1 overcomes resistance to immunotherapy of pancreatic ductal adenocarcinoma through inhibiting ATG9A-dependent degradation of MHC-1.
Zhang Z; Song B; Wei H; Liu Y; Zhang W; Yang Y; Sun B
Drug Resist Updat; 2024 Mar; 73():101040. PubMed ID: 38228036
[TBL] [Abstract][Full Text] [Related]
2. Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance.
Deng Y; Xia X; Zhao Y; Zhao Z; Martinez C; Yin W; Yao J; Hang Q; Wu W; Zhang J; Yu Y; Xia W; Yao F; Zhao D; Sun Y; Ying H; Hung MC; Ma L
Nat Commun; 2021 Dec; 12(1):7041. PubMed ID: 34873175
[TBL] [Abstract][Full Text] [Related]
3. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I.
Yamamoto K; Venida A; Yano J; Biancur DE; Kakiuchi M; Gupta S; Sohn ASW; Mukhopadhyay S; Lin EY; Parker SJ; Banh RS; Paulo JA; Wen KW; Debnath J; Kim GE; Mancias JD; Fearon DT; Perera RM; Kimmelman AC
Nature; 2020 May; 581(7806):100-105. PubMed ID: 32376951
[TBL] [Abstract][Full Text] [Related]
4. Selective autophagy of MHC-I promotes immune evasion of pancreatic cancer.
Yamamoto K; Venida A; Perera RM; Kimmelman AC
Autophagy; 2020 Aug; 16(8):1524-1525. PubMed ID: 32459143
[TBL] [Abstract][Full Text] [Related]
5. Combined MEK and STAT3 Inhibition Uncovers Stromal Plasticity by Enriching for Cancer-Associated Fibroblasts With Mesenchymal Stem Cell-Like Features to Overcome Immunotherapy Resistance in Pancreatic Cancer.
Datta J; Dai X; Bianchi A; De Castro Silva I; Mehra S; Garrido VT; Lamichhane P; Singh SP; Zhou Z; Dosch AR; Messaggio F; Ban Y; Umland O; Hosein PJ; Nagathihalli NS; Merchant NB
Gastroenterology; 2022 Dec; 163(6):1593-1612. PubMed ID: 35948109
[TBL] [Abstract][Full Text] [Related]
6. CDK1/2/5 inhibition overcomes IFNG-mediated adaptive immune resistance in pancreatic cancer.
Huang J; Chen P; Liu K; Liu J; Zhou B; Wu R; Peng Q; Liu ZX; Li C; Kroemer G; Lotze M; Zeh H; Kang R; Tang D
Gut; 2021 May; 70(5):890-899. PubMed ID: 32816920
[TBL] [Abstract][Full Text] [Related]
7. DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma.
Fitzgerald AA; Wang S; Agarwal V; Marcisak EF; Zuo A; Jablonski SA; Loth M; Fertig EJ; MacDougall J; Zhukovsky E; Trivedi S; Bhatia D; O'Neill V; Weiner LM
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34737215
[TBL] [Abstract][Full Text] [Related]
8. Progranulin mediates immune evasion of pancreatic ductal adenocarcinoma through regulation of MHCI expression.
Cheung PF; Yang J; Fang R; Borgers A; Krengel K; Stoffel A; Althoff K; Yip CW; Siu EHL; Ng LWC; Lang KS; Cham LB; Engel DR; Soun C; Cima I; Scheffler B; Striefler JK; Sinn M; Bahra M; Pelzer U; Oettle H; Markus P; Smeets EMM; Aarntzen EHJG; Savvatakis K; Liffers ST; Lueong SS; Neander C; Bazarna A; Zhang X; Paschen A; Crawford HC; Chan AWH; Cheung ST; Siveke JT
Nat Commun; 2022 Jan; 13(1):156. PubMed ID: 35013174
[TBL] [Abstract][Full Text] [Related]
9. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
10. Targeting the bicarbonate transporter SLC4A4 overcomes immunosuppression and immunotherapy resistance in pancreatic cancer.
Cappellesso F; Orban MP; Shirgaonkar N; Berardi E; Serneels J; Neveu MA; Di Molfetta D; Piccapane F; Caroppo R; Debellis L; Ostyn T; Joudiou N; Mignion L; Richiardone E; Jordan BF; Gallez B; Corbet C; Roskams T; DasGupta R; Tejpar S; Di Matteo M; Taverna D; Reshkin SJ; Topal B; Virga F; Mazzone M
Nat Cancer; 2022 Dec; 3(12):1464-1483. PubMed ID: 36522548
[TBL] [Abstract][Full Text] [Related]
11. Dynamic profiling of immune microenvironment during pancreatic cancer development suggests early intervention and combination strategy of immunotherapy.
Yang J; Zhang Q; Wang J; Lou Y; Hong Z; Wei S; Sun K; Wang J; Chen Y; Sheng J; Su W; Bai X; Liang T
EBioMedicine; 2022 Apr; 78():103958. PubMed ID: 35316682
[TBL] [Abstract][Full Text] [Related]
12. TGFβ-derived immune modulatory vaccine: targeting the immunosuppressive and fibrotic tumor microenvironment in a murine model of pancreatic cancer.
Perez-Penco M; Weis-Banke SE; Schina A; Siersbæk M; Hübbe ML; Jørgensen MA; Lecoq I; Lara de la Torre L; Bendtsen SK; Martinenaite E; Holmström MO; Madsen DH; Donia M; Ødum N; Grøntved L; Andersen MH
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600556
[TBL] [Abstract][Full Text] [Related]
13. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.
Kim VM; Blair AB; Lauer P; Foley K; Che X; Soares K; Xia T; Muth ST; Kleponis J; Armstrong TD; Wolfgang CL; Jaffee EM; Brockstedt D; Zheng L
J Immunother Cancer; 2019 May; 7(1):132. PubMed ID: 31113479
[TBL] [Abstract][Full Text] [Related]
14. IRAK4 Signaling Drives Resistance to Checkpoint Immunotherapy in Pancreatic Ductal Adenocarcinoma.
Somani VK; Zhang D; Dodhiawala PB; Lander VE; Liu X; Kang LI; Chen HP; Knolhoff BL; Li L; Grierson PM; Ruzinova MB; DeNardo DG; Lim KH
Gastroenterology; 2022 Jun; 162(7):2047-2062. PubMed ID: 35271824
[TBL] [Abstract][Full Text] [Related]
15. Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6C(low) F4/80(+) Extratumoral Macrophages.
Beatty GL; Winograd R; Evans RA; Long KB; Luque SL; Lee JW; Clendenin C; Gladney WL; Knoblock DM; Guirnalda PD; Vonderheide RH
Gastroenterology; 2015 Jul; 149(1):201-10. PubMed ID: 25888329
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.
Xie Y; Zhu S; Zhong M; Yang M; Sun X; Liu J; Kroemer G; Lotze M; Zeh HJ; Kang R; Tang D
Gastroenterology; 2017 Nov; 153(5):1429-1443.e5. PubMed ID: 28764929
[TBL] [Abstract][Full Text] [Related]
17. MHC class II molecules on pancreatic cancer cells indicate a potential for neo-antigen-based immunotherapy.
Baleeiro RB; Bouwens CJ; Liu P; Di Gioia C; Dunmall LSC; Nagano A; Gangeswaran R; Chelala C; Kocher HM; Lemoine NR; Wang Y
Oncoimmunology; 2022; 11(1):2080329. PubMed ID: 35655709
[TBL] [Abstract][Full Text] [Related]
18. CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma.
Muth ST; Saung MT; Blair AB; Henderson MG; Thomas DL; Zheng L
Cancer Lett; 2021 Feb; 499():99-108. PubMed ID: 33271264
[TBL] [Abstract][Full Text] [Related]
19. Nano-Econazole Enhanced PD-L1 Checkpoint Blockade for Synergistic Antitumor Immunotherapy against Pancreatic Ductal Adenocarcinoma.
Li Q; Qin S; Tian H; Liu R; Qiao L; Liu S; Li B; Yang M; Shi J; Nice EC; Li J; Lang T; Huang C
Small; 2023 Jun; 19(23):e2207201. PubMed ID: 36899444
[TBL] [Abstract][Full Text] [Related]
20. UBL4A inhibits autophagy-mediated proliferation and metastasis of pancreatic ductal adenocarcinoma via targeting LAMP1.
Chen H; Li L; Hu J; Zhao Z; Ji L; Cheng C; Zhang G; Zhang T; Li Y; Chen H; Pan S; Sun B
J Exp Clin Cancer Res; 2019 Jul; 38(1):297. PubMed ID: 31288830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
